JP2015519355A5 - - Google Patents

Download PDF

Info

Publication number
JP2015519355A5
JP2015519355A5 JP2015514499A JP2015514499A JP2015519355A5 JP 2015519355 A5 JP2015519355 A5 JP 2015519355A5 JP 2015514499 A JP2015514499 A JP 2015514499A JP 2015514499 A JP2015514499 A JP 2015514499A JP 2015519355 A5 JP2015519355 A5 JP 2015519355A5
Authority
JP
Japan
Prior art keywords
antibody
seq
tlr3
binding
tlr3 polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015514499A
Other languages
English (en)
Japanese (ja)
Other versions
JP6356120B2 (ja
JP2015519355A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2013/061173 external-priority patent/WO2013178736A1/en
Publication of JP2015519355A publication Critical patent/JP2015519355A/ja
Publication of JP2015519355A5 publication Critical patent/JP2015519355A5/ja
Application granted granted Critical
Publication of JP6356120B2 publication Critical patent/JP6356120B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015514499A 2012-05-31 2013-05-30 Tlr3結合剤 Expired - Fee Related JP6356120B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261653652P 2012-05-31 2012-05-31
US61/653,652 2012-05-31
US201261670289P 2012-07-11 2012-07-11
US61/670,289 2012-07-11
US201261679923P 2012-08-06 2012-08-06
US61/679,923 2012-08-06
PCT/EP2013/061173 WO2013178736A1 (en) 2012-05-31 2013-05-30 Tlr3 binding agents

Publications (3)

Publication Number Publication Date
JP2015519355A JP2015519355A (ja) 2015-07-09
JP2015519355A5 true JP2015519355A5 (enExample) 2016-06-02
JP6356120B2 JP6356120B2 (ja) 2018-07-11

Family

ID=48576992

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015514499A Expired - Fee Related JP6356120B2 (ja) 2012-05-31 2013-05-30 Tlr3結合剤

Country Status (10)

Country Link
US (1) US9944712B2 (enExample)
EP (1) EP2855527B1 (enExample)
JP (1) JP6356120B2 (enExample)
CN (1) CN104379603B (enExample)
AU (1) AU2013269652B2 (enExample)
CA (1) CA2874918A1 (enExample)
DK (1) DK2855527T3 (enExample)
ES (1) ES2695151T3 (enExample)
MX (1) MX361773B (enExample)
WO (1) WO2013178736A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2451844T3 (en) 2009-07-10 2015-07-27 Innate Pharma Tlr3-retention agents
MX361773B (es) 2012-05-31 2018-12-17 Innate Pharma Agentes de ligación a tlr3.
EP2996715A1 (en) * 2013-05-14 2016-03-23 Innate Pharma Methods for restoring corticosteroid sensitivity
TW202506185A (zh) 2017-01-20 2025-02-16 法商賽諾菲公司 抗TGF-β抗體及其用途
AR110755A1 (es) * 2017-01-20 2019-05-02 Genzyme Corp Anticuerpos dirigidos a hueso
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5776427A (en) 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
US5491084A (en) 1993-09-10 1996-02-13 The Trustees Of Columbia University In The City Of New York Uses of green-fluorescent protein
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
AR006928A1 (es) 1996-05-01 1999-09-29 Pioneer Hi Bred Int Una molecula de adn aislada que codifica una proteina fluorescente verde como marcador rastreable para la transformacion de plantas, un metodo para laproduccion de plantas transgenicas, un vector de expresion, una planta transgenica y celulas de dichas plantas.
EP1988166A1 (en) 1997-05-07 2008-11-05 Schering Corporation Human Toll-like receptor proteins, related reagents and methods
ATE230277T1 (de) 1997-06-13 2003-01-15 Genentech Inc Stabilisierte antikörperformulierung
EP1345968A2 (en) 2000-12-28 2003-09-24 Altus Biologics Inc. Crystals of whole antibodies and fragments thereof and methods for making and using them
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
US20050123536A1 (en) 2001-11-20 2005-06-09 Che-Leung Law Treatment of immunological disorders using anti-dc30 antibodies
CA2480059C (en) 2002-03-22 2015-11-24 Amrad Operations Pty. Ltd. Monoclonal antibody against interleukin-13 receptor alpha 1 (il-13r.alpha.1)
JP2004016021A (ja) 2002-06-12 2004-01-22 Japan Science & Technology Corp 抗体および阻害剤並びにそれを用いた形質転換方法および形質転換キット
CA2494104A1 (en) 2002-07-31 2004-04-22 Seattle Genetics, Inc. Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders
AR051836A1 (es) * 2004-11-30 2007-02-14 Centocor Inc Antagonistas de receptor 3 simil toll metodos y usos
ES2435775T3 (es) 2005-10-27 2013-12-23 Janssen Biotech, Inc. Moduladores de receptor tipo Toll 3, procedimientos y usos
NZ569236A (en) 2005-12-08 2012-06-29 Medarex Inc Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and their use
WO2008127347A1 (en) 2006-07-21 2008-10-23 Diadexus, Inc. Pro115 antibody compositions and methods of use
WO2008049897A1 (en) 2006-10-27 2008-05-02 Ablynx N.V. Intranasal delivery of polypeptides and proteins
WO2008140826A1 (en) 2007-05-15 2008-11-20 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
AU2008345179A1 (en) * 2007-12-26 2009-07-09 Centocor, Inc. Cynomolgus toll-like receptor 3
AU2009239655B2 (en) 2008-04-25 2014-05-22 Innate Pharma Improved TLR3 agonist compositions
US20130090457A1 (en) 2008-10-31 2013-04-11 Janssen Biotech, Inc. Toll-Like Receptor 3 Antagonists for the Treatment of Metabolic and Cardiovascular Diseases
KR101683033B1 (ko) 2008-10-31 2016-12-06 얀센 바이오테크 인코포레이티드 톨-유사 수용체 3 길항제
US8460659B2 (en) 2008-10-31 2013-06-11 Janssen Biotech, Inc. Toll-like receptor 3 antagonists for the treatment of metabolic and cardiovascular diseases
HUE028021T2 (en) * 2009-04-29 2016-11-28 Janssen Biotech Inc Pen-like receptor antagonists
DK2451844T3 (en) 2009-07-10 2015-07-27 Innate Pharma Tlr3-retention agents
ES2438774T3 (es) 2009-12-11 2014-01-20 Deutsches Krebsforschungszentrum Anticuerpo que se une a parvovirus H-1
US20140065154A1 (en) 2011-01-12 2014-03-06 Innate Pharma Tlr3 binding agents
MX361773B (es) 2012-05-31 2018-12-17 Innate Pharma Agentes de ligación a tlr3.

Similar Documents

Publication Publication Date Title
JP2017504577A5 (enExample)
JP2014518883A5 (enExample)
JP2017527272A5 (enExample)
MX2012007318A (es) Proteina de fusion de la region constante del anticuerpo-cd47 tetravalente para usarse en terapia.
JP2020521751A5 (enExample)
WO2018057735A8 (en) Antibodies for siglec-15 and methods of use thereof
JP2012143232A5 (enExample)
JP2015508757A5 (enExample)
JP2013518055A5 (enExample)
JP2015537044A5 (enExample)
JP2011500091A5 (enExample)
JP2016539096A5 (enExample)
JP2017526632A5 (enExample)
NZ599140A (en) Antibodies that specifically bind to the epha2 receptor
JP2017500018A5 (enExample)
JP2010502183A5 (enExample)
RU2018128215A (ru) Антитела против mica
NZ610075A (en) Cxcr2 binding polypeptides
JP2016532693A5 (enExample)
JP2019510739A5 (enExample)
JP2016185981A5 (enExample)
JP2009521909A5 (enExample)
AR088455A1 (es) Anticuerpos que antagonizan cd40l
JP2007536932A5 (enExample)
JP2010533498A5 (enExample)